Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus sunitinib in previously untreated advanced or metastatic renal cell carcinoma
NL-OMON55761Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in renal cell carcinoma (RCC) comparing Nivolumab + ipilimumab with Sunitinib monotherapy (2 arms). Primary endpoints: Progression-free survival and Overall survival. Started Jan 2015; status: recruiting.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON55761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55761.